Effectiveness of Brolucizumab in Pretreated Patients With nAMD in the Real-world Setting in Gulf Countries United Arab of Emirates, Kuwait , Bahrain , Oman and Qatar
Status: Terminated
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The study is a prospective and retrospective, observational, single-arm, non-randomized cohort study of ocular treatment with intravitreal injections of brolucizumab in nAMD patients. This study will be conducted prospectively and retrospectively (for patients who had their first brolucizumab injection before study start) using data collected in a standardized manner.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:
• Diagnosis of nAMD
• Patients with ≥18 years of age at index
• Receipt of at least one injection of brolucizumab (not necessarily the first one) during the index period
• Signed informed consent
Locations
Other Locations
United Arab Emirates
Novartis Investigative Site
Abu Dhabi
Time Frame
Start Date: 2022-04-13
Completion Date: 2023-03-13
Participants
Target number of participants: 3
Treatments
Brolucizumab
patients who received their first injection of Brolucizumab either during the active recruitment period (1 year prospective) or during the 6 months pre-start of the recruitment (6 months retrospective)
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals